European markets have recently experienced modest gains, with the pan-European STOXX Europe 600 Index benefiting from easing geopolitical tensions and strong corporate earnings. For investors interested in exploring beyond the well-known companies, penny stocks—often smaller or newer firms—can still hold significant potential despite their somewhat outdated name. In this article, we explore several European penny stocks that stand out for their financial resilience and growth potential.
Top 10 Penny Stocks In Europe
Name
Share Price
Market Cap
Financial Health Rating
Ariston Holding (BIT:ARIS)
€3.79
€1.31B
★★★★★★
Orthex Oyj (HLSE:ORTHEX)
€4.35
€77.25M
★★★★★★
Lucisano Media Group (BIT:LMG)
€1.02
€15.15M
★★★★☆☆
Angler Gaming (NGM:ANGL)
SEK3.60
SEK269.95M
★★★★★★
Angler Gaming (DB:0QM)
€0.31
€247.45M
★★★★★★
Verkkokauppa.com Oyj (HLSE:VERK)
€2.245
€101.32M
★★★★★☆
Libertas 7 (BME:LIB)
€3.24
€68.89M
★★★★★☆
Nurminen Logistics Oyj (HLSE:NLG1V)
€0.84
€67.82M
★★★★★★
High (ENXTPA:HCO)
€3.66
€70.92M
★★★★★★
Deceuninck (ENXTBR:DECB)
€2.05
€283.4M
★★★★★★
Click here to see the full list of 290 stocks from our European Penny Stocks screener.
Here’s a peek at a few of the choices from the screener.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS, oncology, and hematology disorders, with a market cap of €216.73 million.
Operations: The company generates its revenue from the biotechnology segment, amounting to €10.93 million.
Market Cap: €216.73M
Oryzon Genomics, with a market cap of €216.73 million and annual sales of €10.93 million, is making strides in the biotech sector despite being unprofitable. The company’s short-term assets exceed both its short and long-term liabilities, indicating solid financial health. Recent developments include the European Medicines Agency’s approval for a Phase II study of iadademstat in essential thrombocythemia, showcasing its potential in oncology and hematology. Oryzon’s management team is experienced, though the board is relatively new. Earnings are forecast to grow significantly by 51.67% annually, reflecting positive future prospects amidst ongoing clinical trials.
BME:ORY Financial Position Analysis as at May 2026
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Pricer AB (publ) offers in-store digital solutions across Europe, the Middle East and Africa, the Americas, and Asia-Pacific with a market cap of SEK645.60 million.
Operations: Pricer generates revenue through its in-store digital solutions across Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
Market Cap: SEK645.6M
Pricer AB, with a market cap of SEK645.60 million, recently reported Q1 2026 earnings showing a return to profitability with net income of SEK6.4 million compared to a loss last year. Despite volatile share prices and declining profit margins from 4.6% to 0.6%, Pricer’s financial health is supported by short-term assets exceeding liabilities and more cash than debt. The company is expanding its electronic shelf label technology through significant agreements like the USD51 million contract with Sobeys in Canada, showcasing its potential for growth despite past negative earnings trends and low Return on Equity at 1.3%.
OM:PRIC B Financial Position Analysis as at May 2026
Simply Wall St Financial Health Rating: ★★★★★★
Overview: 4Mass Spólka Akcyjna is involved in the manufacture and distribution of make-up products, with a market cap of PLN104.33 million.
Operations: The company’s revenue is primarily derived from the production and distribution of cosmetic products, totaling PLN107.88 million.
Market Cap: PLN104.33M
4MASS Spólka Akcyjna, with a market cap of PLN104.33 million, reported improved Q1 2026 earnings with revenue of PLN29.05 million and net income rising to PLN3.79 million from the previous year. Despite this growth, profit margins have decreased from 16.4% to 9.6%, and the company experienced negative earnings growth over the past year at -42.6%. However, its financial stability is underscored by more cash than debt and short-term assets exceeding both short- and long-term liabilities significantly, while trading at a substantial discount to estimated fair value suggests potential investment appeal in the penny stock space.
WSE:4MS Revenue & Expenses Breakdown as at May 2026 Turning Ideas Into Actions
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:ORY OM:PRIC B and WSE:4MS.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com